santa cruz biotechnology, inc.
SCBT Logo

Willkommen!        Produkt(e) im Warenkorb.     Bestellen
 

G Protein Effectors and Antagonists

  • C3A Receptor Agonist
    A G protein-coupled receptor protein involved in the complement system.
    Katalog #CAS NummerSummenformelMenge
    sc-214644944997-60-8C27H35N3O21 mg/5 mg
  • CID 2745687
    Katalog #CAS NummerSummenformelMenge
    sc-362725264233-05-8C17H19F2N5O2S10 mg/50 mg
  • Compound 48/80 trihydrochloride
    Oligomeric mixture of condensation products of N-methyl-p-methoxyphenethylamine and formaldehyde. Activates G proteins by a mechanism analogous to that of mastoparan.
    Katalog #CAS NummerSummenformelMenge
    sc-20073694724-12-6C32H46N3O3 ·3HCl100 mg/500 mg
  • Dimethyl-W84 dibromide
    Very potent allosteric modulator of muscarinic receptors, selective for M2-receptors. Retards the dissociation of the antagonist N-methylscopolamine. pKA=7.08, p(αKA)=6.75, pEC550,diss=6.77.
    Katalog #CAS NummerSummenformelMenge
    sc-202140402475-33-6C34H48Br2N4O45 mg
  • EHT 1864
    Has been reported to be an inhibitor of Rac family GTPases via guanine nucleotide displacement. This compound has also been shown to modulate amyloid precursor protein (APP) processing which blocks Aβ 40 and Aβ 42 production.
    Katalog #CAS NummerSummenformelMenge
    sc-361175754240-09-0C25H27F3N2O4S•2HCl10 mg/50 mg
  • FIPI
    Isoforms of phospholipase D (PLD) cleave the head group from phospholipids, releasing the second messenger phosphatidic acid (PA), which can produce changes in Ras activation, cell spreading, stress fiber formation, chemotaxis, and membrane vesicle trafficking. FIPI is a derivative of halopemide which potently inhibits both PLD1 (IC50 = 25 nM) and PLD2 (IC50 = 20 nM). It also prevents PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis. FIPI has good pharmacokinetic parameters in rats, with a half-life greater than five hours, a Cmax that, at 363 nM, is greater than 10-fold the IC50 versus PLD2, and bioavailability of 18%
    Katalog #CAS NummerSummenformelMenge
    sc-294594939055-18-2C23H24FN5O21 mg/5 mg
  • GPR30 Agonist, G-1
    A cell-permeable, nonsteroidal, dihydroquinoline compound that acts as a high-affinity agonist for GPR30, the G protein-coupled transmembrane estrogen receptor in ER. It specifically competes with estrogen-binding to GPR30 (Ki = 11 nM), but not to the classical nuclear-residing estrogen receptors, ERα and ERβ (no significant binding upto 1 µM).
    Katalog #CAS NummerSummenformelMenge
    sc-221685881639-98-1C21H18BrNO35 mg
  • Guanosine 5′-O-(2-Thiodiphosphate), Trilithium Salt
    Cell impermeable, non-hydrolyzable analog of guanosine 5'-O-diphosphate (GDP) that competitively inhibits G-protein activation by GTP and GTP analogs.
    Katalog #CAS NummerSummenformelMenge
    sc-29502997952-36-8C10H12Li3N5O10P2S1 mg/5 mg
  • GW 848687X
    Four G protein-coupled receptors, EP1-4, initiate cellular signaling in response to prostaglandin PGE2. The receptor EP1 acts via Gαq to evoke diverse effects, including renal vasoconstriction, bronchoconstriction, hyperalgesia, allodynia, gastric protection, hyperthermia, and sleep inhibition. GW 848687X is a potent and selective EP1 receptor antagonist (IC50 = 2. nM). It has >400-fold selectivity for EP1 relative to the other EP receptor subtypes, the PGD2 receptor, DP1, and the prostacyclin receptor, IP. GW 848687X has 30-fold selectivity over the thromboxane A2 receptor, TP, acting as a functional antagonist at this receptor at higher levels. Its actions against the FP and CRTH2/DP2 receptors have not been characterized. In vivo, GW 848687X has an excellent oral pharmacokinetic profile, with oral bioavailability at 54% in rats and 53% in dogs with a half-life of two hours in both species. In a rat model of chronic inflammatory joint pain, GW 848687X shows complete anti-hyperalgesic activity.
    Katalog #CAS NummerSummenformelMenge
    sc-295034612831-24-0C24H18ClF2NO3500 µg/1 mg
  • Isotetrandrine
    Isotetrandrine is a biscoclaurine alkaloid inhibitor of G protein activation of PLA2 but not PLC or PLD.
    Katalog #CAS NummerSummenformelMenge
    sc-200869477-57-6C38H42N2O61 mg/5 mg
  • Mastoparan (Vespula lewisii)
    Shown to be capable of directly activating G proteins by a mechanism analogous to that of G protein-coupled receptors. Also found to stimulate insulin release by pancreatic islets.
    Katalog #CAS NummerSummenformelMenge
    sc-20083172093-21-1C70H131N19O151 mg
  • Melittin
    Shown to cause apoptosis via induction of reactive oxygen species production in cells. Also reported to inhibit activator protein-1 as well as NF-κB.
    Katalog #CAS NummerSummenformelMenge
    sc-20086837231-28-0C131H229N39O31500 µg
  • Metastin (45-54)
    This is a decapeptide with C-terminally amidated LRF-motif which acts as a potent and selective agonist of AXOR12 and hOT7T175 (a novel human G-protein-coupled receptors). It induces an increase in intracellular Ca2+ levels in CHO/h175 and CHO/AXOR12:Gqi5 cells and exhibits about 8-fold higher receptor binding affinity (Ki = 42 pM) compared to Metastin.
    Katalog #CAS NummerSummenformelMenge
    sc-221883374675-21-5C63H83N17O141 mg
  • N-Formyl-Met-Leu-Phe
    Katalog #CAS NummerSummenformelMenge
    sc-35898859880-97-6C21H31N3O5S5 mg/10 mg
  • N2-[[5-(Diphenylmethyl)-2-furanyl]carbonyl]-L-Arginine hydrate
    A C3a receptor antagonist where the complement component 3a receptor is a G protein-coupled receptor protein involved in the complement system.
    Katalog #CAS NummerSummenformelMenge
    sc-215516945254-73-9 (anhydrous)C24H26N4O4•xH2O1 mg
  • PF9 tetrasodium salt
    Katalog #CAS NummerSummenformelMenge
    sc-362783851265-78-6C18H16N5Na4O13P31 mg
  • Polistes Mastoparan
    This product is a peptide found in wasp venom. It binds to and inhibits calmodulin, a calcium binding protein found in eukaryotic cells.
    Katalog #CAS NummerSummenformelMenge
    sc-20083274129-19-4C77H127N21O181 mg
  • TC-O 9311
    Katalog #CAS NummerSummenformelMenge
    sc-362802444932-31-4C20H19N3O410 mg/50 mg
  • W146 trifluoroacetate salt
    Sphingosine-1-phosphate (S1P) is a bioactive lipid that exhibits a broad spectrum of biological activities including cell proliferation, survival, migration, cytoskeletal organization, and morphogenesis. It exerts its activity by binding to five distinct G protein-coupled receptors, S1P1/EDG-1, S1P2/EDG-5, S1P3/EDG-3, S1P4/EDG-6, and S1P5/EDG-8. W146 is a S1P1 receptor antagonist that exhibits a Ki value of 77 nM for the human receptor in a GTP-γS binding assay with equipotency at the murine S1P1 receptor (2a = W146; 2b = W140 in supplemental material). No agonist or antagonist activity was observed at 10 µM W146 at S1P2, S1P3, or S1P5 receptors. W146 is active in vivo causing skin capillary leakage in murine lung and skin as well as inhibition of S1P1 agonist-induced lymphocyte sequestration. The half-life of W146 in rat blood is 73 minutes.
    Katalog #CAS NummerSummenformelMenge
    sc-296700n.n.C16H27N2O4P•C2F3HO2500 µg/1 mg
  • WZ811
    The CXC chemokine receptor-4 (CXCR4) is a G protein-coupled receptor that is specific for stromal cell-derived factor-1 (SDF-1, CXCL12). Activation of CXCR4 promotes homing of hematopoietic stem cells, chemotaxis and quiescence of lymphocytes, and growth and metastasis of certain cancer cell types. Moreover, CXCR4 on CD4+ T-cells is used by CXCR4-selective HIV forms as a gateway for T-cell infection. WZ811 is a potent inhibitor of binding of an SDF-1 peptide mimic to CXCR4 (EC50 = 0. nM). It prevents SDF-1/CXCL12-mediated modulation of cAMP (EC50 = 1. nM) in cells and blocks SDF-1-induced Matrigel invasion by MDA-MB-231 human breast adenocarcinoma cells (EC50 = 5. nM). The effectiveness of WZ811 in animals remains to be elucidated.
    Katalog #CAS NummerSummenformelMenge
    sc-29670155778-02-4n.n.1 mg/5 mg
  • YS121
    Microsomal prostaglandin E2 synthase-1 (mPGES-1), with cyclooxygenase-2 (COX-2), synthesizes PGE2, which is directly involved in signaling during inflammation, fever, and pain. 5-Lipoxygenase (5-LO) initiates the synthesis of leukotrienes (LTs), which are pro-inflammatory mediators. YS121 is a dual inhibitor of mPGES-1 (IC50 = 3.9 μM) and 5-LO (IC50 = 4. μM). It effectively inhibits PGE2 and LT synthesis in both cell free and intact cell assays. Moreover, YS121 (1. mg/kg, intraperitoneal) reduced pleural levels of PGE2 and LTB4 while blocking exudate formation and leukocyte infiltration in carrageenan-induced rat pleurisy. YS121 has minor effects on COX-1 and COX-2, inhibiting these enzymes 24.8% and 38%, respectively, at 10 μM
    Katalog #CAS NummerSummenformelMenge
    sc-296707916482-17-2C20H26ClN3O2S1 mg/5 mg